SmartZyme Biopharma
Improving Enzymes for Glucose Monitoring
Company Overview
Snapshot
Founded in November 2013 by David Baram, SmartZyme Biopharma operates with 1–10 employees. The company has raised $10.5M across 3 funding rounds from 3 investors.
Business overview
SmartZyme Biopharma develops novel enzymes for various medical applications, leveraging its proprietary protein engineering platform, Provolution. This platform combines advanced computational methods with a random mutagenesis approach to design enzymes with improved efficacy and safety. The company initially focuses on products for diabetes patients, including glucose monitoring test strips and patches, operating within the Health Tech & Life Sciences sector.
Strategic signal
In December 2018, SmartZyme Biopharma's spin-off, Carnot BioSciences, partnered with HemoShear Therapeutics to develop protein-based therapeutics for rare metabolic diseases. This collaboration signals SmartZyme's strategic expansion into broader therapeutic areas through its spin-off entities, validating its core protein engineering technology for diverse applications beyond its initial focus on diabetes.
Company Intelligence Q&A
- What is SmartZyme Biopharma's primary focus?
- SmartZyme Biopharma focuses on developing novel enzymes for medical applications, particularly for diabetes patients, including glucose monitoring test strips and patches.
- What is the Provolution platform?
- The Provolution platform is SmartZyme Biopharma's proprietary protein engineering technology that combines advanced computational methods with random mutagenesis to design enzymes with improved clinical performance, efficacy, and safety.
- When was SmartZyme Biopharma founded?
- SmartZyme Biopharma was founded in November 2013.
- Which investors participated in SmartZyme Biopharma's March 2018 funding round?
- In March 2018, SmartZyme Biopharma received funding from Virtus Inspire Ventures and OrbiMed.
- What significant partnership did a SmartZyme spin-off announce?
- In December 2018, Carnot BioSciences, a spin-off of SmartZyme Biopharma, partnered with HemoShear Therapeutics to develop protein-based therapeutics for rare metabolic diseases.